glutathione for cancer patients Can Have Antioxidant? Application of glutathione depletion in

Aging Cell 19 , 115 (2020)

Following subcutaneous administration in clinical models: Both components demonstrate prolonged absorption with peak plasma concentrations occurring 24-72 hours post-injection GLP3 exhibits approximately 6-day half-life enabling once-weekly dosing Cagrilintide demonstrates 120-165 hour half-life (5-7 days) suitable for weekly administration Lipid conjugation of both peptides enables albumin binding and extended systemic circulation Distribution patterns show systemic exposure with concentration in metabolically active tissues The fatty diacid modifications on both peptides (C20 for GLP3 , eicosanedioic acid for cagrilintide) serve as albumin-binding moieties that dramatically extend plasma residence time compared to native peptides

HRT use increases eGPX activity in all controls, but not in Leu carriers who developed BC at a later stage in life

Medical grade products eliminate that variability

Ebbert JO

PMID: 30144361